Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Gustavo P. Amarante‐Mendes, Aamir Rana, Tarcila Santos Datoguia, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 215-215
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
Govinda Poudel, Molly G. Tolland, Timothy P. Hughes, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3300-3300
Open Access | Times Cited: 39
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Nițulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 35
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane F. Apperley, Jorge E. Cortés, et al.
Leukemia (2024) Vol. 38, Iss. 3, pp. 475-481
Open Access | Times Cited: 17
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
Mohamed El‐Tanani, Hamdi Nsairat, Ismail Matalka, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155161-155161
Open Access | Times Cited: 15
µPhos: a scalable and sensitive platform for high-dimensional phosphoproteomics
Denys Oliinyk, Andreas Will, Felix R Schneidmadel, et al.
Molecular Systems Biology (2024) Vol. 20, Iss. 8, pp. 972-995
Open Access | Times Cited: 9
Exploration of Degrons and Their Ability to Mediate Targeted Protein Degradation
Timothy J. Harris, Darci J. Trader
RSC Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Marcin Cieślak, Marta Słowianek
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 812-812
Open Access | Times Cited: 21
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
Xinping Cao, Xin Jin, Xiaomei Zhang, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 3, pp. 184-211
Open Access | Times Cited: 19
Clinically relevant fusion oncogenes: detection and practical implications
Maxim Sorokin, Elizaveta Rabushko, Julian M. Rozenberg, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 24
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
Jingnan Sun, Ruiping Hu, Mengyuan Han, et al.
International Journal of Biological Sciences (2023) Vol. 20, Iss. 1, pp. 175-181
Open Access | Times Cited: 15
Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
Salma Younes, Mohamed A. Ismail, Rana Al‐Jurf, et al.
Hematology (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 13
Single amino acid–based PROTACs trigger degradation of the oncogenic kinase BCR–ABL in chronic myeloid leukemia (CML)
Jianchao Zhang, Caibing Ma, Yongjun Yu, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 8, pp. 104994-104994
Open Access | Times Cited: 13
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor
Haixia Liu, Qianglong Mi, Xinyu Ding, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114810-114810
Closed Access | Times Cited: 19
The Many Faces of Philadelphia: A Mature T-Cell Lymphoma with Variant Philadelphia-Translocation and Duplication of the Philadelphia Chromosome
Livia Vida, Bálint Horváth, Miklós Egyed, et al.
Hematology Reports (2025) Vol. 17, Iss. 1, pp. 1-1
Open Access
In Vitro Antiviral Assays: A Review of Laboratory Methods
Gabriel Atampugbire, Eureka Adomako, Osbourne Quaye
Assay and Drug Development Technologies (2025)
Closed Access
Evaluation of Cas13d as a tool for genetic interaction mapping
Ghanem El Kassem, Jasmine Hillmer, Michael Boettcher
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment
Ali Golestan, Mohammadrasul Zareinejad, Amin Ramezani
Biomarkers in Medicine (2025), pp. 1-16
Closed Access
Current and future of targeted therapies against BCR::ABL kinases
Jayavel Sridhar, M. Subramanian, Pradeep Kumar Kesavan, et al.
Journal of the Egyptian National Cancer Institute (2025) Vol. 37, Iss. 1
Open Access
Translational transcriptomics for personalized oncology
Anton Buzdin, Alexander Seryakov, Marianna Zolotovskaia, et al.
Elsevier eBooks (2025), pp. 331-396
Closed Access
BCR-ABL: The Molecular Mastermind behind Chronic Myeloid Leukemia
Tara Shammas, Malalage N. Peiris, April N. Meyer, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Identification of potential Abl kinase inhibitors using virtual screening and free energy calculations for the treatment of chronic myeloid leukemia
Beom Soo Kim, Wookyung Yu
Biophysical Chemistry (2025), pp. 107470-107470
Closed Access
Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies
Kari Salokas, Giovanna Dashi, Markku Varjosalo
Cancers (2023) Vol. 15, Iss. 14, pp. 3678-3678
Open Access | Times Cited: 9
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance
Abdulaziz M. Eshaq, Thomas W. Flanagan, Sofie-Yasmin Hassan, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2754-2754
Open Access | Times Cited: 3
[Retracted] CuO‐TiO2‐Chitosan‐Berbamine Nanocomposites Induce Apoptosis through the Mitochondrial Pathway with the Expression of P53, BAX, and BCL‐2 in the Human K562 Cancer Cell Line
Abozer Y. Elderdery, Badr Alzahrani, Siddiqa M. A. Hamza, et al.
Bioinorganic Chemistry and Applications (2022) Vol. 2022, Iss. 1
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top